Latest Articles

Publication Date
All News Scientific
Lisata Therapeutics strikes research partnership to investigate new treatment for endometriosis - Proactive Investors Australia

Lisata Therapeutics strikes research partnership to investigate new treatment for endometriosis Proactive Investors Australia

Published: Oct. 28, 2024, 1:52 p.m.
Read Full Article
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis - StockTitan

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis StockTitan

Published: Oct. 28, 2024, 12:30 p.m.
Read Full Article
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) The Manila Times

Published: Oct. 16, 2024, 8:24 p.m.
Read Full Article
Women’s Health Therapeutics Market Size to Reach USD 61.6 - GlobeNewswire

Women’s Health Therapeutics Market Size to Reach USD 61.6 GlobeNewswire

Published: Oct. 15, 2024, 1:11 p.m.
Read Full Article
Women’s Health Therapeutics Market Size to Reach USD 61.6 Billion by 2032, Driven by Rising Awareness & Technological Advancements - SNS Insider - Business Upturn

Women’s Health Therapeutics Market Size to Reach USD 61.6 Billion by 2032, Driven by Rising Awareness & Technological Advancements - SNS Insider Business Upturn

Published: Oct. 15, 2024, 12:40 p.m.
Read Full Article
(PDF) A comprehensive overview of exosome lncRNAs: emerging biomarkers and potential therapeutics in endometriosis - ResearchGate

(PDF) A comprehensive overview of exosome lncRNAs: emerging biomarkers and potential therapeutics in endometriosis ResearchGate

Published: July 6, 2024, 7 a.m.
Read Full Article
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer - GlobeNewswire

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous …

Published: May 20, 2024, 7 a.m.
Read Full Article
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting - Investor Relations | Karyopharm Therapeutics

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting Investor Relations | Karyopharm Therapeutics

Published: April 24, 2024, 7 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!